Biotech | November 23, 2021
AstraZeneca opens Discovery Centre in Cambridge
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
The cream has an estimated market size of US $ 28 million for twelve months ending Jun 2021 according to IQVIA
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
Subscribe To Our Newsletter & Stay Updated
